Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ProMIS Neurosciences Inc. - Common Shares (NQ:PMN)

8.270 -0.010 (-0.12%)
Delayed Quote Updated: 2:07 PM EDT, Oct 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ProMIS Neurosciences Inc. - Common Shares

< Previous 1 2 3 4 5 Next >
News headline image
ProMIS Neurosciences Appoints Seasoned Alzheimer’s and Neuroscience Executive Ivana Rubino, Ph.D., as Chief Commercial Officer
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
Promis Neurosciences Q2 Earnings Call Highlights ↗
Promis Neurosciences (NASDAQ:PMN) reported second-quarter 2026 results and highlighted blinded six-month interim data from its Phase 1b PRECISE-AD study of PMN310, an investigational antibody for early... 
Via MarketBeat
Topics Earnings
News headline image
ProMIS Neurosciences Reports Q2 2026 Results: Full Earnings Call Transcript ↗
On Thursday, ProMIS Neurosciences (NASDAQ:PMN) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For... 
Via Benzinga
Topics Earnings
News headline image
ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
Promis Reports No ARIA-E in PMN310 Alzheimer’s Trial Interim Data ↗
Promis Neurosciences (NASDAQ:PMN) reported blinded six-month interim data from its Phase 1b PRECISE-AD trial of PMN310, an investigational antibody designed to selectively target toxic amyloid-beta... 
Via MarketBeat
News headline image
ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Gainers Gossamer Bio (NASDAQ:GOSS) shares rose 28.8% to $0.26 during Monday's after-market session. The company's market cap stands at $66.4 million. ProMIS Neurosciences (NASDAQ:PMN) shares increased... 
Via Benzinga
News headline image
ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer’s Disease
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences to Participate in Upcoming Conferences in June
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer’s Disease/Parkinson’s Disease 2026 International Conference (AD/PD™)
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
From ProMIS Neurosciences Inc.
Via GlobeNewswire
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
Which stocks are moving before the opening bell on Friday? ↗
Via Chartmill
News headline image
ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer’s Disease
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer’s trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
Which stocks are experiencing notable movement on Monday? ↗
Looking for insights into the US markets one hour before the close of the markets on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
Top movers in Monday's session ↗
Intrigued by the market activity in the middle of the day on Monday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
News headline image
The market is filled with gapping stocks in Monday's session. ↗
In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down. 
Via Chartmill
News headline image
Wondering what's happening in today's pre-market session? ↗
Let's have a look at what is happening on the US markets before the opening bell on Monday. Below you can find the top gainers and losers in today's pre-market session. 
Via Chartmill
News headline image
ProMIS Neurosciences Announces Reverse Stock Split
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights
From ProMIS Neurosciences Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS